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Abstract 
 
Background Psychosocial and behavioral interventions trials targeting a broad range of 
complex social and behavioral problems such as smoking, obesity and family caregiving have 
proliferated in the past 30 years. At the same time the use of Data and Safety Monitoring 
Boards (DSMBs) to monitor the progress and quality of intervention trials and the safety of 
study participants has increased substantially. Most of the existing literature and guidelines 
for safety monitoring and reporting of adverse events focuses on medical interventions. 
Consequently, there is little guidance for investigators conducting social and behavior trials. 
Purpose This paper summarizes how issues associated with safety monitoring and adverse 
event reporting were handled in the Resources for Enhancing Alzheimer’s Caregiver Health 
(REACH II) program, a multi-site randomized clinical trial, funded by the National Institutes on 
Aging (NIA) and the National Institutes of Nursing Research (NINR), that tested the efficacy 
of a multicomponent social/behavioral intervention for caregivers of persons with Alzheimer’s 
disease.  
Methods A task force was formed to define adverse events for the trial and protocols for 
reporting and resolving events that occurred. The task force conducted a review of existing 
polices and protocols for data and safety monitoring and adverse event reporting and 
identified potential risks particular to the study population. An informal survey regarding data 
and safety monitoring procedures with investigators on psychosocial intervention trials was 
also conducted.  
Results Two categories of events were defined for both caregivers and patients; adverse 
events and safety alerts. A distinction was also made between events detected at baseline 
assessment and those detected post-randomization. Standardized protocols were also 
developed for the reporting and resolution of events that occurred and training of study 
personnel. Results from the informal survey indicated wide variability in practices for data 
safety and monitoring across psychosocial intervention trials. Conclusions Overall, the 
REACH II experience demonstrates that existing guidelines regarding safety monitoring and 
adverse event reporting pose unique challenges for social/behavioral intervention trials. 
Challenges encountered in the REACH II program included defining and classifying adverse 
events, defining “resolution” of adverse events and attributing causes for events that 
occurred. These challenges are highlighted and recommendations for addressing them in 
future studies are discussed.    
Introduction  
During the past 30 years, psychosocial and behavioral interventions designed to maintain 
and improve health and quality-of-life have proliferated. Researchers have targeted a 
broad range of complex social and behavioral problems such as smoking, obesity, medical 
compliance and family caregiving. Recently, there has also been a growing demand for 
evidence-based practice. Clinicians, social agencies and policy makers increasingly 
require evidence about real-world effects of treatments when making decisions about 
investing in intervention programs. In response, the randomized clinical trial (RCT) design, 
recognized as the gold standard for evaluating medical interventions, is commonly used to 
evaluate the effectiveness of behavioral intervention approaches.  
 
To ensure that RCTs meet the highest scientific standards, many aspects of the design 
and conduct of a clinical trial such as participant recruitment, treatment adherence, 
intervention outcomes and participant safety must be carefully monitored. Toward this end, 
the use of independent Data and Safety Monitoring Boards (DSMBs) to monitor the 
progress and quality of a trial and participant safety has increased substantially [1,2]. In 
fact, in an effort to improve the quality of clinical research and ensure the protection of 
human subjects, the National Institutes of Health (NIH) has issued guidelines and 
regulations to increase the use of data and safety monitoring within clinical trials. It is now 
the policy of NIH that each Institute and Center should have a system for the appropriate 
oversight and monitoring of the conduct of clinical trials to ensure the safety of the 
participants and the validity and integrity of the data. A DSMB is required for all Phase III 
multisite clinical trials involving potential risks to participants and may be required for 
Phase I or II trials, and even smaller intervention studies if the study population is 
vulnerable or other study characteristics support the need for an external board [3]. The 
Federal Drug Administration (FDA) has also recently issued draft guidelines on the 
formation and responsibilities of DSMBs for trials subject to FDA oversight. Theses 
guidelines are fairly consistent with procedures followed for NIH-funded trials [4].  
 
The primary role of a DSMB is to ensure the safety of trial participants, through review of 
adverse events. A key secondary role is to preserve the quality and credibility of the trial in 
order to provide reliable results to clinical and policy communities. Although there is 
general agreement about the basic roles of DSMBs, how they are used and function varies 
widely across trials and sponsoring agencies [5]. Many issues such as determination of 
when DSMBs are needed, methods for conducting interim data analyses and 
confidentiality of interim results remain controversial [6,7]. For example, questions often 
arise about policies used to guide decisions about the safety and efficacy of trials. 
Although a number of statistical approaches are available for assessing interim data these 
statistical procedures in and of themselves are seldom sufficient for making 
recommendations about trial termination and continuation. There are several cases 
reported in the literature where strict adherence to the stopping rules established for a trial 
would have led to less than optimal conclusions about the potential benefits or harm of a 
treatment [6,8,9]. A related controversy is whether access to interim outcome data should 
be restricted to DSMB members. The rationale for masking is preservation of trial integrity 
and credibility and protection from bias. Arguments for unmasking are based on the 
premise that excluding trial members from access to interim outcomes may result in 
erroneous conclusions about treatment effects as DSMB members may not have access 
to key information they need to interpret the results of the interim analysis. Clearly safety 
monitoring can mean different things to different people, depending on their relationship to 
a particular study.  
 
Controversies also exist regarding the definition and reporting of adverse events. 
Adverse events are generally defined as any unfavorable or unintended symptom, sign or 
disease associated with a medical treatment or procedure that may or may not be related 
to the treatment or procedure [10]. Investigators are typically required to report all AEs and 
assess severity whether or not they are related to study treatments. In principle, the term 
adverse event should be non-judgmental with regard to the relationship between treatment 
and the event. AEs can be associated with the treatment, the disorder or behavior being 
targeted, a concurrent disorder or treatment, or it may be entirely unrelated.  
 
Existing guidelines for the definitions and reporting of AEs are somewhat broad and 
vague. The current FDA guideline requires reporting of AEs that are “serious and 
unexpected” whereas the NIH requires reporting of “unanticipated problems” posing risks 
to study participants [11]. Clearly, there can be considerable variability in the interpretation 
of terms such as “serious”, “unexpected” and “unanticipated”. Furthermore, existing 
policies offer little guidance regarding required documentation and protocols for reporting. 
Support for this view can be found in recent reviews of the AE literature which have 
demonstrated fairly wide variance in the terms used to describe adverse events (eg, 
adverse events versus side effects versus complications) as well as variations, even within 
trials, in AE reporting, especially with respect to judgments of severity or relatedness 
[12,13]. Consistency in AE documentation, characterization and evaluation is important 
since lack of consistency can ultimately affect decisions about treatment adoption. 
Judgments of causality must also take into account the complex dynamic interplay 
between the inherent risks of the intervention and contextual factors such as comorbidities 
related to a disease that can influence the type and frequency of AEs that occur within a 
trial. Lack of understanding of these factors and their potential relationship to study 
treatments can lead to biasing in data reporting and interpretation as well as poor 
decisions about when to stop a trial.  
 
Issues surrounding safety monitoring and AE reporting are even more complex for 
social and behavioral intervention trials. Because most of the existing literature regarding 
AEs is based on medical interventions, there exists little guidance for investigators 
conducting social and behavior trials. To help fill this gap, this paper reports how issues 
associated with safety monitoring and reporting of adverse events were handled in the 
Resources for Enhancing Alzheimer’s Caregiver Health (REACH II) program. Data are 
also reported from an informal survey conducted with investigators of other currently active 
psychosocial intervention trials regarding data and safety monitoring procedures. The 
overall goal of the paper is to identify the challenges of applying existing guidelines for 
monitoring clinical trials for safety to social/behavioral intervention trials and to make 
suggestions as to how they might be addressed in future studies.  
 
Overview of the REACH II program  
REACH II was a multisite randomized clinical trial, funded by the National Institutes on 
Aging (NIA) and the National Institutes of Nursing Research (NINR) that tested the efficacy 
of a multicomponent social/behavioral intervention for caregivers of persons with 
Alzheimer’s disease. The randomized cohort consisted of 212 Hispanic/Latino, 219 white 
Caucasian, and 211 black/African-American caregivers recruited from five sites in the US: 
Birmingham, AL; Miami, FL; Memphis, TN; Palo Alto, CA; Philadelphia, PA. The study also 
included a coordinating center at the University of Pittsburgh.  
Eligibility  
Eligibility criteria for caregivers included being Hispanic/Latino, white/Caucasian, or 
black/African-American; being over the age of 21; living with or sharing cooking facilities 
with the patient; providing care for a relative with Alzheimer’s Disease and Related 
Disorders (ADRD) for a minimum of four hours per day for at least the past six months; 
caring for a patient with memory or behavior problems, and feeling overwhelmed, or angry, 
or having crying spells, or feeling cut off from family or friends because of caregiving 
demands. Caregivers were excluded if they were involved in another caregiver 
intervention study, participated in the earlier REACH I trial, or had an illness that would 
prevent them from participating for at least six months. Other requirements were logistical 
and included having a telephone, planning to remain in the geographic area for at least six 
months, and competency in either English or Spanish.  
 
In order to be eligible for the study, caregivers had to confirm that their relative had a 
diagnosis of Alzheimer’s disease or related dementia. Patients who scored above 23 on 
the Mini-Mental State Exam [14] were required to have a physician’s diagnosis of 
Alzheimer’s disease or a related disorder.  
Protocol  
Participants were screened for eligibility, given a baseline assessment, and subsequently 
randomized to treatment or control condition within each of the three ethnic groups. 
Caregivers were assessed a second time six months later after the intervention was 
completed. The intervention was designed to improve the quality of life of caregivers in 
multiple domains. Therefore, the primary outcome was a multivariate quality of life 
indicator that assessed caregiver burden, depressive symptoms, self-care, social support, 
and patient problem behaviors. In addition, caregiver clinical depression and patient 
institutional placement were assessed.  
Study design  
The design of the intervention was guided by consideration of the existing literature and 
findings from the multisite REACH I [15,16]. The evidence from both sources indicated that 
caregiving presents multiple challenges and that there is no single, consistently effective 
method for achieving clinical significance effects among caregivers. As a result, the 
intervention was based on a risk appraisal approach and five areas linked to caregiver 
stress health processes: burden, depression, self-care, social support and care recipient 
problem behaviors [17] were matched to five corresponding intervention components. 
Because there is considerable variability in the needs of caregiver/care recipients, a 
structured risk appraisal was administered at baseline and dosing was adjusted to level of 
risk present within each area. For example, a person who had minimal problems with 
depression would only receive a small dose of the intervention component designed to 
improve emotional wellbeing. To deliver the intervention in a cost effective manner the 
intervention was administered using a combination of in-home visits augmented by 
telephone/computer technology in 12 sessions over six months. In addition, five telephone 
administered cross-site support group sessions were available to intervention arm 
participants. Caregivers were also provided with a Caregiver Notebook that contained 
basic educational materials as well as other instructional materials provided by the 
interventionist during the home sessions.  
 
In contrast, caregivers in the control arm received a packet of basic educational 
materials and two brief (<15 minute) telephone “check-in calls” at three and five months 
post randomization. They were also invited to participate in a workshop on dementia and 
caregiving following the six-month assessment. All materials were available in English and 
Spanish.  
Overview of safety monitoring in REACH II  
Because REACH II was a multisite intervention trial and involved a vulnerable population 
(caregivers and dementia patients) an independent DSMB was required by the sponsoring 
agencies. The members of the DSMB were identified by the sponsoring agencies, with 
recommendations from the Trial Steering Committee, prior to the start of the study. The 
five members included experts in intervention research, caregiving, biostatistics, and 
ethics. The primary responsibilities of the DSMB included monitoring of participant 
recruitment and safety, protocol compliance, and data quality. The DSMB met twice 
yearly; once in person and once by conference call. They received data reports a month 
prior to each meeting that contained information about participant recruitment, retention, 
participant characteristics and adverse events. In addition to the DSMB members meeting 
attendees included the program officers from the NIA and the NINR, the study statistician, 
the Principal Investigator of the Coordinating Center and the Chair of the REACH II 
Steering Committee.  
 
At the initial meeting, the DSMB reviewed the study protocol (eg, informed consent 
forms, intervention protocols, data collection instruments), and agreed upon data reporting 
requirements (frequency, type of data and reporting format). They also reviewed the 
definitions of adverse events and protocols for resolution of those events adopted for the 
trial (Table 1). At subsequent meetings the DSMB reviewed the progress of the study (eg, 
recruitment by race/ethnicity at each site, protocol deviations, intervention adherence, 
adverse events, site visit summaries, data quality, attrition, effectiveness of randomization 
procedures) and made recommendations concerning its continuation. The decisions of the 
DSMB were considered advisory to the NIH. Formal stopping rules were not specified for 
the trial.  
 
The DSMB worked with the Coordinating Center and the program officers to choose a 
monitoring approach that best suited the study. An interim data analysis, performed by the 
trial statistician, was also conducted. To avoid potential bias, all site investigators and the 
PI of the Coordinating Center were masked to the results of the interim analyses. The 
Coordinating Center generated minutes for each of the DSMB meetings which were then 
submitted to the NIA, NINR and the sites who then distributed the minutes to the local 
Institutional Review Boards (IRB).  
 
 
 
Challenges encountered in the REACH II program 
  
Defining and classifying adverse events (AEs)  
One of the initial challenges faced by the REACH II investigators was defining and 
classifying AEs for the trial. To facilitate this process a task force with representatives from 
each of the five sites, the coordinating center, and the sponsoring agencies was formed. 
Given that this was a multisite trial, it was important to ensure that the definition of AEs 
was standardized across the five intervention sites. In addition, as the focus of the trial 
was the dyad, AEs needed to be defined for both the caregiver and the care recipient.  
 
Also, the intervention was based on a risk appraisal approach and a baseline 
assessment, which included measures of depression, quality of care, care recipient 
problem behaviors was administered prior to randomization. Thus, AEs and potential risks 
to the participants could be detected prior to the start of the intervention. For example, the 
risk appraisal questionnaire asked caregivers if the care recipient had threatened to harm 
him or herself or others, had access to a gun or was still driving. Although, events detected 
at baseline could not be attributable to the intervention, because of ethical and IRB 
requirements they needed to be reported and addressed. Consideration also needed to be 
given to the characteristics of the participant population and contextual factors surrounding 
the caregiving situation. For example, dementia patients are likely to be elderly and have 
medical or behavioral comorbidities such as wandering or aggression. Likewise, it is not 
uncommon for caregivers to suffer from depressive symptoms. While these types of 
events do not fall under the standard definition of serious AEs they still pose a potential 
risk to the individual. Finally, as noted, the population was ethnically diverse and events 
such as institutionalization of the patient tend to be more common among some caregiver 
populations (eg, non-Hispanic whites) as opposed to others (eg, Hispanics/Latinos) [18].  
 
Based on these considerations, we distinguished among two categories of events: 
adverse events and safety alerts. The definition of “adverse event” was consistent with 
traditional definitions of AEs and included events such as death, hospitalization and 
emergency room visits. “Safety alerts” were events that were relevant to the study 
population and posed safety risks to study participants. Examples of safety alerts included 
caregivers having symptoms of depression or the care recipient driving (Table 1). A 
distinction was also made between events that were detected at baseline (baseline adverse 
events and baseline safety alerts) versus those that occurred following randomization and 
the six-month follow-up assessment (adverse events and safety alerts).  
Defining “resolution”  
A second task involved defining what constituted “resolution” of a safety alert or an 
adverse event. This task was challenging as events such as institutionalization are 
common among dementia patients and often permanent. For example, a question arose 
regarding resolution of patient institutionalization. Should resolution be defined as the 
return of the patient to the home setting or simply knowledge that placement occurred and 
the reason for the placement decision? Obviously, placement of patients who were 
permanently placed would never be “resolved” if the definition of resolution of this event 
was the patient returning to home. The final definitions of resolution for AEs and safety 
alerts are presented in Table 1.  
The definitions of adverse events and safety alerts and protocols for event resolution 
were submitted to the DSMB for review and approval. An important aspect of this process 
was educating the DSMB about the nature of the intervention and the characteristics of the 
target population. Although all of the members of the DSMB had experience with clinical 
trials and expertise in intervention research some of the members had limited expertise 
with caregiving and dementia patients. Following approval by the DSMB, study personnel 
(assessors and interventionists) at the five intervention sites and the Coordinating Center 
were trained in protocols for identification, reporting and resolution of AEs and safety 
alerts. These protocols were also included in the manual of operations. 
 
As shown in Table 2, the most common events among caregivers were evidence of high 
levels of depressive symptoms. Among care recipients, the most common events were 
hospitalization, comments related to death, institutionalization and death. Also, as 
indicated there was some variation in frequency of event according to ethnicity of the 
dyad. Institutionalization, access to a gun and continued driving was more common among 
the white/Caucasian care recipients as compared to the Hispanic/Latino and black 
American care recipients.  
Reporting requirements and attribution  
Developing a standardized reporting system was also complicated given differences in 
requirements among the site IRBs. Some sites were required to report all events to the  
local IRB irrespective of event severity whereas other sites were only required to report  
AEs and not safety alerts. The DSMB required reporting of all events.  
 
To help ensure consistency in reporting across the sites, adverse events and safety 
alerts were tracked using standardized forms that recorded the date of the event, type of 
event, attribution of the event (eg, was it intervention related), whether the event was 
resolved or controlled and the resolution date. These forms were completed by the site PI 
or designee (eg, clinical supervisor, project coordinator) and faxed to the Coordinating 
Center within 24 hours of learning of the event. Sites were also required to complete an 
Adverse Event Resolution Note which further detailed the specifics of the how the event 
was addressed.  
The issue of attribution proved to be somewhat of a challenge for the REACH II 
program. Events such as hospitalization are common among dementia patients given the 
nature of the illness and the fact that dementia patients tend to be elderly and have other 
comorbid conditions. In fact, in the REACH II trial hospitalizations were the most common 
AE among the care recipients (Table 2). Though unlikely to be related to the intervention, 
the relatively high frequency of hospitalizations generated concern among the members of 
the DSMB, particularly since more were reported for care recipients in the intervention 
condition than in the control arm (Table 3). Because of this concern, the DSMB required 
further analyses of these events. It was determined that the higher frequency of 
hospitalizations among care recipients in the intervention condition was likely due to 
greater contact between the interventionists and caregiver who received the intervention 
and not related to the intervention. Similar issues arose for care recipient emergency room 
visits. The problems associated with determining attribution experienced in the REACH II 
program highlight the difficulties of applying existing definitions of AEs, developed for 
medical intervention, to social behavioral intervention trials. In addition, this issue 
underscores the importance of ensuring that members of the DSMB understand the nature 
of the intervention, the disease or behavioral problem of interest and the characteristics of 
the target population. A lack of understanding of these factors among DSMB members can 
potentially lead to erroneous decisions about the safety and impact of the intervention.  
Results of the informal survey  
As noted, the authors were interested in ascertaining to what extent the adverse event 
issues encountered in the REACH II project were shared by other researchers conducting 
psychosocial clinical trials. To address this question, we conducted an informal survey 
with Principal Investigators of other trials via questionnaire. The questionnaire consisted 
of 22 items, including yes/no, checklist, and open ended questions regarding 
challenges/difficulties encountered related to data safety monitoring and the reporting of 
adverse events.  
Sample  
Trials (N = 84) were identified from the NIH.GOV and Clinical Trials.Gov websites. The 
search was limited to behavioral and social intervention trials or trials that combined 
behavioral and medical interventions and were currently active. The survey instrument 
was mailed to the Principal Investigator of the identified trials. The response rate was 
49% (N = 41).  
 
The interventions being evaluated in the studies that responded included cognitive and 
psychosocial interventions (47%), education (18%), skills training (14%), exercise (10%), 
medically-related (8%) and mind/body interventions (2%). The study populations included 
patients with chronic diseases (39%), mental-health problems (29%), family caregivers 
(15%), and older persons with physical frailty (7%) or cognitive impairment (2%). Eighty 
percent (N = 33) of the trials included a control condition such as standard care (42%), 
placebo, information only or no treatment control (38%). The remaining studies did not 
include a control group and were not randomized trials. Seventy-one per cent of the trials 
(N = 29) were multisite.  
 
Data safety monitoring and AEs  
Results of the survey indicated that there was considerable variability among the trials in 
protocols for data and safety monitoring. Fifty-four per cent of the trials had a formal 
DSMB; 37% had a monitoring plan but no external Board, and 10% reported using 
neither. As expected, formal DSMBs were more common among multisite trials (83%) as 
compared to single site trials (41%). Only 31% of the studies with DSMBs had formal 
stopping rules for trial termination. The type of data reported to the DSMB varied. Most 
trials reported data related to the occurrence of serious (83%) or other types of AEs 
(71%), participant recruitment (71%) and retention (76%). However, reporting of data 
related to participant baseline characteristics (51%), data quality (46%) and data 
timeliness was less common (37%). Several trials did not report AEs or serious AEs.  
Only 78% of the trials had established protocols for defining adverse events; 60% had 
established protocols for reporting the attribution/causality of serious adverse events and 
45% had such protocols for other-than-serious events. AEs were identified through a 
variety of sources including participant self-report (77%), interventionists interaction with 
the participant (77%) or standardized questionnaires at schedules assessments (54%). In 
most studies attribution was determined by the Principal Investigator (85%) or the IRB 
(67%). Similarly resolution was typically determined by the Principal Investigator (64%) or 
the IRB (64%).  
Key challenges  
Investigators were also asked to describe any challenges or problems that arose during 
the trial related to safety monitoring or reporting of adverse events. Commonly reported 
problems included definition of what constituted an adverse event (especially for those 
trials that included a vulnerable population), determination of attribution and lack of 
consistency in reporting of AES by study staff. Overall, the list of problems was similar to 
the challenges faced by the REACH II investigators.  
Discussion  
In an effort to improve the quality of clinical research and ensure the safety of research 
participants, safety monitoring is becoming an integral component of clinical research 
projects. Potential benefits associated with safety monitoring include early identification of 
treatments that pose risk to individuals or which are likely to be ineffective, information on 
the extent to which recruited participants reflect the profile anticipated and overall 
improvements in data quality. Summary data on adverse events can also provide useful 
insights into the needs of study populations and aid in the design of future intervention 
approaches. Currently however, guidelines for data safety monitoring are somewhat 
broad and vary across sponsoring agencies, including agencies within the federal 
government. As a result there is wide variability in policies and protocols for conducting 
data and safety monitoring and much debate surrounding issues related to the use of 
DSMBs, stopping rules, and definition and reporting of adverse events. Questions 
regarding safety monitoring are especially complex for social/behavioral intervention 
trials.  
 
This paper describes the protocols adopted for safety monitoring within the REACH II 
project, a multisite randomized clinical trial that evaluated the efficacy of a 
multicomponent psychosocial intervention for caregivers of dementia patients. Unique 
characteristics of the REACH II program included a risk-appraisal based intervention 
approach, a focus on the dyad, and inclusion of an ethnically diverse and vulnerable 
study population. Challenges that were encountered in developing a plan for safety 
monitoring in the REACH II program included defining and classifying adverse events, 
defining “resolution” of adverse events and attributing causes for events that occurred. 
Results of an informal survey suggest that these problems are not unique and common in 
other behavioral trials.  
 
On the basis of the REACH II experience, the following is a summary of 
recommendations for implementing the existing guidelines for safety monitoring in social 
behavioral trials. Our intent is to provide suggestions rather than a prescription as it is 
recognized that models for data and safety monitoring vary according to the need and 
characteristics of a particular trial.  
Data and safety monitoring boards (DSMBs)  
One issue that needs to be addressed is the need for, composition and role of the data 
safety and monitoring board (DSMB). Prior to the start of the trial the role of the DSMB 
also needs to be clearly defined as do protocols for data reporting and interim analyses. 
In some cases having the DSMB members serve only in a scientific advisory capacity as 
opposed to a formal board who makes decisions about trial termination may be sufficient. 
In other cases, a formal DSMB may not be needed and a safety monitoring plan may be 
adequate. The degree of monitoring should be based on the study’s risk profile. Factors 
to be considered in the risk assessment include the characteristics of the population being 
studied; risks associated with the intervention from prior studies and potential risks to the 
study population in the absence of the intervention [19]. For example, for vulnerable 
populations such as dementia patients a higher risk must be assumed.  
 
If a formal DSMB is required, protocols for the structure, function and responsibilities of 
the DSMB as well as the format and content of DSMB reports, statistical procedures and 
monitoring guidelines should be clearly established before the start of the trial. Ellenberg 
and colleagues [7] and the DAta MOnitoring Committees: Lessons, Ethics, Statistics 
(DAMOCLES) study group [20] maintain that intervention trials would benefit from the 
development of a charter outlining the protocols and responsibilities for data and safety 
monitoring. Both groups provide examples of such a charter that encompass guidelines 
for DSMB membership, responsibilities of the DSMB, protocols for the organization of 
DSMB meetings, data reporting, interim data analyses and decision making and reporting 
hierarchies. However, these charters while useful as guidelines are primarily oriented at 
medical intervention trials and may need to be adapted for psychosocial interventions. 
Furthermore, they do not address the issue of defining adverse events and determining 
what constitutes “satisfactory” resolution of events that occur. We recommend that these 
proposed charters be considered a reference and perhaps checklist for the issues that 
need to be addressed if a formal DSMB is required for a trial.  
 
If a formal DSMB is required, the committee must include individuals with expertise in 
the clinical area being studied and the target population. Expertise in both is needed to 
ensure appropriate interpretation of adverse events. For example, in the case of REACH 
II having expertise in both care-giving and Alzheimer’s Disease was important. Having 
individuals with some knowledge and experience with clinical trials and data safety 
monitoring is also valuable. In any case, it is essential that all members of a DSMB have 
a thorough understanding of the intervention protocol, the problem area being addressed 
and the characteristics of the study population.  
 
However, the size of the committee is also an important consideration as the number of 
members is likely to have an impact on the quality of the decision process.  
Identifying and defining adverse events  
Careful consideration also needs to be given defining what constitutes an adverse event 
for a trial. Defining adverse events, according to criteria developed for medical trials, may 
not be appropriate for some types of interventions. As demonstrated in REACH II events 
such as hospitalization and placement are common among patients with dementia and 
unlikely to be related to behavioral interventions. Reporting these types of events and 
investigating their causes may place undue burden on study personnel, DSBM members 
and local IRBs. A more effective strategy would be to have DSMB members and 
investigators reach consensus about those adverse events important for assuring the 
safety and well-being of specific study population enrolled in the study. These judgments 
should be based on the types of individuals and problems being studied, the nature of the 
interventions being tested, as well as the findings from related prior research. Since 
ascertaining the causes of adverse events can be labor intensive and costly, the focus 
should be on adverse events that reasonably might be linked to the intervention.  
 
Protocols for monitoring and reporting adverse events  
Protocols also need to be developed for standardized tracking and reporting of adverse 
events. These protocols need to include delineation of the type of data that needs to be 
reported (eg, group versus site level data), and the timing and frequency of data reports. 
This is especially important for multisite trials to ensure consistency in data reporting. 
Where possible, there should also be consistency in reporting requirements between local 
IRBs and the sponsoring agencies. This would help minimize duplication of effort and 
costs associated with data reporting. For example, in the case of REACH II, differences in 
event report forms required by local IRBs and those developed for the caused a 
duplication of effort for study personnel. Equally important is insuring that study personal 
are trained in protocols for identifying and reporting adverse events. Criteria also need to 
be established for assigning event attribution.  
Interim data analysis  
Finally, procedures for the interim data analyses need to be clearly established prior to 
initiating the trial. Important issues that need to be considered include the outcome 
measures that will be included in the analyses, who will conduct the analyses, who will 
be included in the discussion of the analysis, and the extent to which the investigators 
are masked with respect to study outcomes. With respect to the issue of masking, we 
recommend that, at minimum, the study statistician be included in the discussion of the 
results of the interim analyses to ensure that the findings are interpreted appropriately 
by DSMB members.  
 
Overall, there are a number of issues with data safety monitoring that need to be 
addressed within clinical trials. These issues are likely to become more salient as the 
demand for evidence-based treatment and translational research continues to grow. 
Practices for data and safety monitoring need to achieve an appropriate balance 
between the protection of research participants and maximizing the quality and scientific 
validity of research trials. It is hoped that the lessons learned from the REACH II trial will 
help other investigators establish protocols for data and safety monitoring in social/ 
behavioral intervention trials.  
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Table 1  Definitions of adverse events and safety alerts and protocols for resolution used in the REACH II program 
Baseline adverse 
events Resolution
a
 Adverse events Resolution* 
Caregiver death Not applicableb Caregiver death The PI or designee (eg, clinical 
supervisor, project coordinator) 
obtained information regarding 
the circumstances of the event 
Caregiver 
hospitalization 
Not applicable Caregiver 
hospitalization 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
obtained information regarding 
the reason for the hospitalization 
and the status of the caregiver 
Caregiver 
institutionalization 
Not applicable Caregiver 
institutionalizati
on 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
obtained information regarding 
the reason for the 
institutionalization and the status 
of the caregiver 
Caregiver emergency 
visit 
Not applicable Caregiver 
emergency 
room visit 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the reason for the 
emergency room visit and how 
the problem was handled (eg, 
received treatment, is currently 
under treatment and/or is being 
monitored by health care 
provider) 
Care recipient death Not applicable Care recipient 
death 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
obtained information regarding 
the circumstances of the event 
Care recipient 
hospitalization 
Not applicable Care recipient 
hospitalization 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the reason for the 
hospitalization and the status of 
the care recipient 
Care recipient 
institutionalization 
Not applicable Care recipient 
institutionalizati
on 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the care giver to 
determine the reason and 
planned duration of the 
institutionalization 
Care recipient 
emergency room 
visit 
Not applicable Care recipient 
emergency 
room visit 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the reason for the visit 
and how the problem is being 
handled (eg, received treatment, 
is currently under treatment 
and/or monitoring by health care 
provider) 
                 
                           continued 
    
Baseline safety 
alerts Resolution Safety alerts Resolution 
Caregiver severe 
medical problemc 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
determined the nature of the 
problem and how the problem 
was handled (eg, received 
treatment, is currently under 
treatment and/or monitoring by 
health care provider) and 
referred the CG to their primary 
other care physician (or other 
health care professional) 
Caregiver severe 
medical 
problem 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
determined the nature of the 
problem and how the problem 
was handled (eg, received 
treatment, is currently under 
treatment and/or monitoring by 
health care provider) and referred 
the CG to their primary care 
physician (or health care 
professional) 
Caregiver CESD 
score ≥ 15 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
discuss the seriousness of the 
situation and referred them to 
their primary care physician (or 
other health care professional) 
to discuss their symptoms 
Caregiver CESD 
score ≥ 15 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to discuss 
the seriousness of the situation 
and referred them to their primary 
care physician (or other health 
care professional) to discuss their 
symptoms 
Caregiver abuse The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the nature of the 
situation and to devise a plan of 
action.  The caregiver was 
advised to contact their primary 
care physician.  If the caregiver 
refused or was not able to 
control the situation Adult 
Protective Services may be 
contact by the site 
Caregiver abuse The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the nature of the 
situation and to devise a plan of 
action.  The caregiver was 
advised to contact their primary 
care physician.  If the caregiver 
refused or was not able to control 
the situation Adult Protective 
Services may be contact by the 
site 
Care recipient severe 
medical problem 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the nature of the 
problem and how the problem 
was handled (eg, received 
treatment, is currently under 
treatment and/or monitoring by 
health care provider) and 
referred the CG to their primary 
care physician (or other health 
care professional) 
Care recipient 
severe medical 
problem 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the nature of the 
problem and how the problem 
was handled (eg, received 
treatment, is currently under 
treatment and/or monitoring by 
health care provider) and referred 
the CG to their primary care 
physician (or other health care 
professional) 
Care recipient 
threatens to hurt 
him/herself three 
or more times in 
the past week 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
discuss the statements made 
by the care recipient and 
devise a plan of action with the 
CG.  The CG was advised to 
monitor the patient and if the 
situation persists to contact 
their primary care physician. 
Care recipient 
threatens to 
hurt him/herself 
three or more 
times in the 
past week 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to discuss 
the statements made by the care 
recipient and devise a plan of 
action with the CG.  The CG was 
advised to monitor the patient and 
if the situation persists to contact 
their primary care physician. 
    
                                continued 
    
Baseline safety 
alerts Resolution Safety alerts Resolution 
Care recipient has 
access to a gun 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
discuss the safety implications 
and devise a plan of action to 
block the care recipient’s 
access to the gun.  If the CG 
refused or was unable to block 
the CR’s access Adult 
Protective Services may have 
been contacted.  If it appears 
that an assessor or 
interventionist was in danger 
the CGs/CR’s participation in 
the study was terminated 
Care recipient has 
access to a 
gun 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to discuss 
the safety implications and devise 
a plan of action to block the care 
recipient’s access to the gun.  If 
the CG refused or was unable to 
block the CR’s access Adult 
Protective Services may have 
been contacted.  If it appears that 
an assessor or interventionist was 
in danger the CGs/CR’s 
participation in the study was 
terminated (unless it was the six-
month followup) 
Care recipient driving The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
discuss the safety implications 
of the CR driving and devise a 
plan of action to stop the care 
recipient from driving.  CGs 
who were randomized to the 
control condition were sent the 
material on driving and 
dementia.  CGs who were 
randomized to the intervention 
condition were encouraged to 
read the materials in the 
Caregiver Notebook related to 
driving 
Care recipient 
driving 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to discuss 
the safety implications of the CR 
driving and devise a plan of action 
to stop the care recipient from 
driving.  CGs were encouraged to 
read the materials that they have 
received related to driving   
Care recipient abuse  The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the nature of the 
situation and devise a plan of 
action.  If the caregiver refused 
or was not able to control the 
situation Adult Protective 
Services may have been 
contacted by the site 
Care recipient 
abuse 
The PI or designee (eg, clinical 
supervisor, project coordinator) 
contacted the caregiver to 
determine the nature of the 
situation and devise a plan of 
action.  If the caregiver refused or 
was not able to control the 
situation Adult Protective Services 
may have been contacted by the 
site 
 
a
Resolution means that the problem has been addressed with the caregiver; where appropriate (eg, CR driving; access to a 
gun) and a plan of action and recommendations are discussed and no further action by the research team is required. 
b
Resolution of baseline adverse events was considered as not applicable due to the fact that the intervention had not yet 
begun, therefore there was no concern about event being caused by intervention and the occurrence of this type of event at 
baseline would have precluded the dyad from being randomized in the trial. 
c
Severe medical problem is defined as an illness (medical or emotional) or injury that impairs a person’s daily functioning or 
causes high levels of subjective distress. Examples might include: urinary tract infection, chronic cough, flu, broken limb 
(resulting from a fall). 
 
 
 
 
 
 
 
 
Table 2 Adverse events and safety alerts in REACH II by ethnicity 
 No. events at baseline 
 Hispanic White Black Total 
No. Safety alerts or AEs/No. participants 96/212 132/219 66/211 294/642 
CG events     
     CG CES-D score 15 or more 55 52 38 145 
     CG hospitalization 0 0 0 0 
     CG emergency room visit 0 0 0 0 
     CG several medical problem 0 0 0 0 
     CG institutionalization 0 0 0 0 
     CG death 0 0 0 0 
     CG other event 1 0 0 1 
CR events     
     CR hospitalization 2 1 1 4 
     CR institutionalization 0 0 0 0 
     CR emergency room visit 0 1 1 2 
     CR death 0 0 0 0 
     CR severe medical problem 0 0 0 0 
     CR commented of death 3 X or more 23 23 10 56 
     CR threatened to hurt 3 X or more 4 2 0 6 
     CR access to a gun 3 26 10 39 
     CR driving 5 27 5 37 
     CR other event 3 0 1 4 
 No. events post-randomization 
 Hispanic White Black Total 
No. safety alerts or  AEs/No. participants 138/212 203/219 158/211 499/642 
CG events      
     CG CES-D score 15 or more 40 29 24 93 
     CG hospitalization 5 14 15 34 
     CG emergency room visit 6 8 7 21 
     CG several medical problem 8 1 5 14 
     CG institutionalization 0 1 0 0 
     CG death 0 0 1 0 
     CG other event 5 2 5 12 
CR events     
     CR hospitalization 25 46 40 111 
     CR institutionalization 7 29 9 45 
     CR emergency room visit 7 15 5 27 
     CR death 10 16 20 46 
     CR severe medical problem 6 2 5 13 
     CR commented of death 3 X or more 13 11 8 32 
     CR threatened to hurt 3 X or more 0 2 2 4 
     CR access to a gun 0 12 6 18 
     CR driving 3 15 4 22 
     CR other event 3 0 2 5 
 
*CG/CR abuse events did not occur. 
 
 
 
Table 3 Post-randomization adverse events and safety alerts by intervention condition  
 
                             No. events 
 Control                 Intervention         Total 
No. safety alerts or    
     AEs/No. participants  203/319  296/323  499/642  
CG eventsa     
     CG CES-D score 15 or moreb 59  34  93  
     CG hospitalization  12  22  34  
     CG emergency room visit 3  18  21  
     CG severe medical problem 1  13  14  
     CG institutionalization  1  0  1  
     CG death  1  0  1  
     CG other event  6  6  12  
CR eventsa     
     CR hospitalization  29  82  111  
     CR institutionalization  22  23  45  
     CR emergency room visit 3  24  27  
     CR death  22  24  46  
     CR severe medical problem 2  11  13  
     CR commented of death 3 X or more 19  13  32  
     CR threatened to hurt 3 X or more 3  1  4  
     CR access to a gun  8  10  18  
     CR driving  11  11  22  
     CR other event  1  4  5  
 
            a
CG/CR abuse events did not occur. 
        
b
Based on 10 item version of CES-D (possible range 0–30). 
